NasdaqCM:CYRX

Stock Analysis Report

Executive Summary

Cryoport, Inc. provides temperature controlled logistics solutions to the life sciences industry in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Snowflake

Fundamentals

Flawless balance sheet and slightly overvalued.

Risks

  • Cryoport has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Cryoport's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.08%

NasdaqCM:CYRX

1.9%

US Medical Equipment

2.1%

US Market


1 Year Return

76.0%

NasdaqCM:CYRX

13.6%

US Medical Equipment

-0.04%

US Market

CYRX outperformed the Medical Equipment industry which returned 14% over the past year.

CYRX outperformed the Market in United States of America which returned 0.2% over the past year.


Share holder returns

CYRXIndustryMarket
7 Day-0.08%1.9%2.1%
30 Day22.0%-0.2%-3.2%
90 Day36.5%10.2%2.8%
1 Year76.0%76.0%14.5%13.6%2.2%-0.04%
3 Year1092.5%1092.5%70.2%65.0%41.5%32.3%
5 Year338.5%338.5%133.6%106.8%55.0%37.8%

Price Volatility Vs. Market

How volatile is Cryoport's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cryoport undervalued based on future cash flows and its price relative to the stock market?

46%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Cryoport's share price is below the future cash flow value, and at a moderate discount (> 20%).

Cryoport's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Cryoport is loss making, we can't compare its value to the US Medical Equipment industry average.

Cryoport is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Cryoport, we can't assess if its growth is good value.


Price Based on Value of Assets

Cryoport is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Cryoport expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

60.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Cryoport's revenue is expected to grow significantly at over 20% yearly.

Cryoport is not considered high growth as it is expected to be loss making for the next 1-3 years.

Cryoport's revenue growth is expected to exceed the United States of America market average.

Unable to compare Cryoport's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Cryoport's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Cryoport will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Cryoport performed over the past 5 years?

11.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Cryoport does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Cryoport's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Cryoport's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Cryoport has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Cryoport has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Cryoport improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Cryoport's financial position?


Financial Position Analysis

Cryoport is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Cryoport's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Cryoport's level of debt (13.5%) compared to net worth is satisfactory (less than 40%).

Cryoport had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 6.9x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Cryoport has sufficient cash runway for more than 3 years based on current free cash flow.

Cryoport has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -1.6% each year.


Next Steps

Dividend

What is Cryoport's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Cryoport's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Cryoport's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Cryoport has not reported any payouts.

Unable to verify if Cryoport's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Cryoport has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Cryoport's salary, the management and board of directors tenure and is there insider trading?

4.6yrs

Average management tenure


CEO

Jerrell Shelton (74yo)

6.8yrs

Tenure

US$2,772,401

Compensation

Mr. Jerrell W. Shelton, also known as Jerry, has been the Chief Executive Officer and President of CryoPort, Inc. since November 5, 2012 and has been its Chairman of the Board since October 2015. Mr. Shelt ...


CEO Compensation Analysis

Jerrell's remuneration is about average for companies of similar size in United States of America.

Jerrell's compensation has increased whilst company is loss making.


Management Age and Tenure

4.6yrs

Average Tenure

54yo

Average Age

The tenure for the Cryoport management team is about average.


Board Age and Tenure

4.5yrs

Average Tenure

69yo

Average Age

The tenure for the Cryoport board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Robert Stefanovich (54yo)

    CFO, Treasurer & Corporate Secretary

    • Tenure: 8.2yrs
    • Compensation: US$832.32k
  • Jerrell Shelton (74yo)

    Chairman

    • Tenure: 6.8yrs
    • Compensation: US$2.77m
  • Raymond Takahashi

    Executive Officer

    • Tenure: 0.0yrs
  • David Petreccia

    Executive Officer

    • Tenure: 0.0yrs
  • Bret Bollinger (52yo)

    Chief Technology Officer

    • Tenure: 1.9yrs
    • Compensation: US$174.52k
  • Mark Sawicki

    Chief Commercial Officer

    • Tenure: 4.6yrs
  • Thomas Heinzen

    Vice President of Corporate Development & Investor Relations

    • Tenure: 0.0yrs
  • Phil Wilson

    Senior Vice President of Global Operations & Supply Chain

    • Tenure: 0.6yrs

Board Members

  • Richard Berman (76yo)

    Lead Director

    • Tenure: 3.8yrs
    • Compensation: US$331.46k
  • Bill Taaffe (70yo)

    Member of Commercial Advisory Board

    • Tenure: 6.6yrs
  • Ed Zecchini (58yo)

    Independent Director

    • Tenure: 5.9yrs
    • Compensation: US$301.46k
  • Bob Hariri (60yo)

    Independent Director

    • Tenure: 3.9yrs
    • Compensation: US$310.46k
  • Rick Kriss

    Member of Advisory Board

    • Tenure: 11.6yrs
  • Jerrell Shelton (74yo)

    Chairman

    • Tenure: 6.8yrs
    • Compensation: US$2.77m
  • Larry O’Toole

    Member of Advisory Board

    • Tenure: 0.0yrs
  • Ram Mandalam (54yo)

    Independent Director

    • Tenure: 5.2yrs
    • Compensation: US$296.46k
  • Dan Hancock (69yo)

    Independent Director

    • Tenure: 0.6yrs

Company Information

Cryoport, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cryoport, Inc.
  • Ticker: CYRX
  • Exchange: NasdaqCM
  • Founded: 1999
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$844.618m
  • Shares outstanding: 35.59m
  • Website: https://www.cryoport.com

Number of Employees


Location

  • Cryoport, Inc.
  • 17305 Daimler Street
  • Irvine
  • California
  • 92614
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CYRXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2005

Biography

Cryoport, Inc. provides temperature controlled logistics solutions to the life sciences industry in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a clo ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/22 23:55
End of Day Share Price2019/08/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.